Trial Profile

Clinical trial of MVI 816 in combination with a PD-1 pathway inhibitor for the treatment of prostate cancer.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVI 816 (Primary) ; Pembrolizumab (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

08 Nov 2016 According to a Madison Vaccines media release, this trial will guide expanded trials for treating late-stage cancers.
08 Nov 2016 Interim results published in the Madison Vaccines Media Release.
27 Oct 2016 According to a Madison Vaccines media release, data from this trial will be presented at the at the Society for Immunotherapy of Cancer annual meeting in November.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com